近日,中国国家药监局(NMPA)官网公示,某慢性阻塞性肺病(COPD)长效雾化支气管扩张剂上市申请获批。这一创新药物的成功上市,将为中国COPD患者带来全新治疗选择。在该药物III期临床研究的关键阶段,医渡科技凭借数字化患者招募服务,以高效的执行能力大幅缩短患者入组周期,入组速率提升30%+,保障临床试验顺利推进。COPD创新药获批,满足临床治疗新需求COPD是一种发病率上升的慢性炎症性肺部疾病,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.